Paclitaxel in the management of ovarian cancer
作者： Robin L Jones , Vasilios Karavasilis , Stanley B Kaye
关键词:
摘要: Paclitaxel, in combination with a platinum compound, is the current first-line standard of care for epithelial ovarian cancer following surgery. Randomized trials have demonstrated that paclitaxel plus carboplatin easier to administer and associated less toxicity than cisplatin, but has equivalent efficacy. Single-agent activity recurrent disease large randomized trial clearly shown significant benefit retreating this agent agent. Evaluation regimens incorporating weekly been undertaken; administration way may an anti-angiogenic effect approach good tolerability. The mechanisms responsible resistance are beginning be understood, novel molecular targeted agents chemotherapy prove successful treating resistant disease.
expert-reviews.com参考文章(113)
A H Calvert, A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel Seminars in Oncology. ,vol. 24, ,(1997)
K Aabo, , M Adams, P Adnitt, DS Alberts, A Athanazziou, V Barley, DR Bell, U Bianchi, G Bolis, MF Brady, HS Brodovsky, H Bruckner, M Buyse, R Canetta, V Chylak, CJ Cohen, N Colombo, PF Conte, D Crowther, JH Edmonson, C Gennatas, E Gilbey, M Gore, D Guthrie, SB Kaye, AH Laing, F Landoni, RC Leonard, C Lewis, PY Liu, C Mangioni, S Marsoni, H Meerpohl, GA Omura, MKB Parmar, J Pater, S Pecorelli, M Presti, W Sauerbrei, DV Skarlos, RV Smalley, HJ Solomon, LA Stewart, JFG Sturgeon, MHN Tattersall, JT Wharton, WW ten Bokkel Huinink, M Tomirotti, W Torri, C Trope, MM Turbow, JB Vermorken, MJ Webb, DW Wilbur, CJ Williams, E Wiltshaw, BY Yeap, Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials British Journal of Cancer. ,vol. 78, pp. 1479- 1487 ,(1998) , 10.1038/BJC.1998.710
D. C. Tormey, K. D. Tutsch, J. K. V. Willson, Santhanam Swaminathan, K. J. Simon, J. L. Grem, D. B. Alberti, D. L. Trump, Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer treatment reports. ,vol. 71, pp. 1179- 1184 ,(1987)
W ten Bokkel Huinink, D Armstrong, A Gordon, J Malfetano, J Carmichael, Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Seminars in Oncology. ,vol. 24, ,(1997)
DeVita Vt, Dedrick Rl, Myers Ce, Bungay Pm, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer treatment reports. ,vol. 62, pp. 1- 11 ,(1978)
Charles R. Geard, Peter B. Schiff, Roy B. Tishler, Eric J. Hall, Taxol Sensitizes Human Astrocytoma Cells to Radiation Cancer Research. ,vol. 52, pp. 3495- 3497 ,(1992)
, , International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute. ,vol. 95, pp. 105- 112 ,(2003) , 10.1093/JNCI/95.2.105
Benjamin K. Tsang, Xiaojuan Yan, Brendan M. Leung, Han C. Dan, Michael Fraser, Jin Q. Cheng, p53 Is a Determinant of X-Linked Inhibitor of Apoptosis Protein/Akt-Mediated Chemoresistance in Human Ovarian Cancer Cells Cancer Research. ,vol. 63, pp. 7081- 7088 ,(2003)
John K. Chan, Huyen Pham, Xue Juan You, Noelle G. Cloven, Robert A. Burger, G. Scott Rose, Kristi Van Nostrand, Murray Korc, Philip J. DiSaia, Hung Fan, Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Research. ,vol. 65, pp. 3243- 3248 ,(2005) , 10.1158/0008-5472.CAN-03-3013
Gordon M. Cragg, Michael R. Boyd, John H. Cardellina, David J. Newman, Kenneth M. Snader, Thomas G. McCloud, Ethnobotany and Drug Discovery: The Experience of the US National Cancer Institute Novartis Foundation Symposia. ,vol. 185, pp. 178- 196 ,(2007) , 10.1002/9780470514634.CH13